



# Practice Re-audit Report

## Demo Practice One

Demo Surgery, 123 Demo Street, Demotown, Demoshire  
AB12 3CD

Practice Code: A12345  
NORTH DEMO PCN  
NHS Demoshire ICB  
Practice List Size: 9,824

Follow-up search results uploaded on Wed 4th Dec 2024  
Initial search results uploaded on Wednesday 23rd Oct 2024



This non-promotional medical resource is funded by AstraZeneca and co-developed with Oberoi Consulting.  
UK HCPs should exercise professional judgment when using this resource.



# Contents

Background	3
Purpose of <b>OneAsthma</b>	4
Prevalence	5
Disease Register Validation	6
<b>OneAsthma</b> Search Rationale	7
Overview of Practice Data	8
Breakdown of Search Cohorts	9
Appendix	14
References	19

# Background

- Asthma is a chronic, heterogenous disease of the airways characterised by airway hyperresponsiveness.<sup>1</sup> It is estimated that 6.5% of adults in England have asthma.<sup>2</sup>
- While poor Inhaled Corticosteroid (ICS) adherence is a concern, regardless of the use of controller medication, high short-acting  $\beta$ -agonist (SABA) use has been found to be associated with poorer clinical outcomes, including exacerbations and mortality, in addition to increased healthcare utilisation.<sup>3</sup>
- Excess SABA prescribing is defined as the prescription of three or more SABA inhalers in 12 months, because this level is associated with more frequent and more severe asthma attacks, as well as mortality.<sup>4</sup>
- Comparing low (1–2) SABA users to extreme (>12) SABA users to show that the 11+ additional SABA prescriptions increase exacerbation-related healthcare utilisation costs by £97,015 per thousand patients.<sup>4</sup>
- The Global Initiative for Asthma no longer recommends treating adolescents and adults with as-needed SABA alone for symptom relief. As these findings reveal high SABA use and associated burden even in patients with mild asthma, there is a need to align SABA prescription practices with current treatment recommendations.<sup>3</sup>

# Purpose of **OneAsthma**

**OneAsthma** aids primary care providers in identifying patients on SABA therapy who show signs of poorly controlled asthma, such as hospital admissions, two or more exacerbations, two or more oral corticosteroid (OCS) prescriptions within 12 months, or poor symptom control with an ACT score of less than 20. These patients may need a review of their inhaler regimen.

Additionally, **OneAsthma** identifies those with potential severe asthma for referral to severe asthma centers.

Severe asthma is a complex condition often driven by various inflammatory pathways. Its symptoms are more challenging to manage, even with high doses of medication, and require more specialised treatments to control symptoms and reduce asthma attacks.<sup>5</sup>

Patients exhibiting poor control, who have used three or more SABAs in the last 12 months and are also prescribed ICS therapy, are segmented further by high strength and other ICS therapy. These cohorts should be reviewed and optimised and, if appropriate, referred to severe asthma centers.

High-strength ICS therapy, as well as SABA and OCS therapies used in the searches, are detailed in the appendix for reference.

**OneAsthma** also includes data quality searches to enable primary care to validate asthma registers.


Current searches for SABA and ICS therapy usage are based on the number of prescription issues recorded over the last 12 months. However, the searches may underestimate total inhaler usage for patients who receive multiple inhalers under a single prescription. In such cases, patients may be categorised into lower usage groups, as the system captures only the number of prescription issues rather than the total number of inhalers dispensed.

# Prevalence

The **2023/24 QOF** data<sup>6</sup> shows that the **Asthma prevalence** in **England** was **6.53%**, while in **NORTH DEMO PCN** the prevalence was **6.89%** and in **NHS Demoshire ICB** it was **6.79%**.

Since baseline, the practice Asthma register has **decreased** by **2 patients**.

The practice currently has **736 patients** on the Asthma register, with the prevalence being **7.49%**, compared with **738 patients** on the Asthma register (**7.52% prevalence**) at baseline.



\* QOF 2023-24

# Disease Register Validation

For a patient to appear on the Asthma register, they must have an appropriate Asthma diagnosis code recorded within their electronic record and current asthma treatment (*in the last 12 months*).

Codes that place patients on the Asthma register can be found in the Appendix.


To identify patients who should be reviewed and coded, access the searches labelled as below from the folder “**Disease Register Validation**”.

Search Number and Description	Number of Patients Baseline	Number of Patients Re-audit	SUGGESTED ACTION
01c. 3+ Inhalers in last 12m - no Asthma / COPD / Respiratory Disease diagnosis	42	39	Review record and code Asthma if appropriate
01d. FEV1/FVC <0.7 + SABA or ICS in last 12m - No Asthma / COPD / Respiratory Disease diagnosis	0	0	
01e. Asthma exacerbation / review / plan + SABA or ICS in last 12m - No Asthma / COPD / Respiratory Disease diagnosis	5	4	
01f. Asthma resolved + SABA or ICS in the last 12m - No other Respiratory Disease diagnosis	5	5	
01g. Most recent PEFr variability >20% + SABA or ICS in last 12m - No other Respiratory Disease diagnosis	0	0	
01h. Positive reversibility + SABA or ICS in the last 12m - No Asthma / COPD / Respiratory Disease diagnosis	0	0	


Each newly diagnosed Asthma patient added to the register, is worth an extra **£15.26** of QOF income<sup>6,7</sup> (*assuming all 45 QOF points achieved*).

# OneAsthma Search Rationale

To prioritise patients for review, the Asthma register (excluding those with COPD, on palliative care register or with exercise induced asthma) is initially segmented by current treatment as shown below:



Each of the above groups are then further segmented by indicators of poor control as listed below, for patients **6-11 years old** and **12+ years old**:



Each patient will only appear in one group

# Overview of Practice Data

The table below shows a breakdown of **683 patients** on the asthma register\* by inhalers issued along with indicators of poor asthma control.

		Search Groups				
		50 patients Issued SABA monotherapy (no ICS) in 12 months <i>Searches 02 &amp; 07</i>	204 patients Issued ≤ 2 SABA + ICS in 12 months <i>Searches 03 &amp; 08</i>	119 patients Issued 3-5 SABA + ICS in 12 months** <i>Searches 04 &amp; 09</i>	109 patients Issued ≥ 6 SABA + ICS in 12 months** <i>Searches 05 &amp; 10</i>	198 patients Issued ICS monotherapy (no SABA) in 12 months <i>Searches 06 &amp; 11</i>
Indicators of Poor Control	10 patients Hospital admission or > 2 exacerbations	0 (1)‡	3 (4)‡	0 (1)‡	5 (6)‡	2 (3)‡
	32 patients ≥ 2 Systemic OCS	1 (2)‡	8 (11)‡	6 (10)‡	13 (11)‡	4 (5)‡
	82 patients Poor symptom control or ACT < 20	2 (3)‡	24 (30)‡	15 (11)‡	18 (24)‡	23 (25)‡
	556 patients Other Patients	47 (51)‡	169 (153)‡	98 (98)‡	73 (69)‡	169 (162)‡

\* Excluding those with COPD, on palliative care register or with exercise induced asthma

\*\* These cohorts are split into high and other strength ICS

‡ Number of patients at baseline




# Issued SABA monotherapy (no ICS) in 12 months\*

## Age 6-11 years

**3 Patients** are currently issued **SABA monotherapy (no ICS)** in the previous 12 months\*, compared with **4 at baseline**


The graphs below shows a breakdown of patients with indicators of poor asthma control. To review these patients access **searches 07a to 07d** within the folder named **"02. Issued SABA monotherapy"**.



## Age 12+ years

**47 Patients** are currently issued **SABA monotherapy (no ICS)** in the previous 12 months\*, compared with **53 at baseline**

The graphs below shows a breakdown of patients with indicators of poor asthma control. To review these patients access **searches 02a to 02d** within the folder named **"02. Issued SABA monotherapy"**.




\* Patients on the Asthma Register excluding those with COPD, on palliative care register or with exercise induced asthma

# Issued $\leq 2$ SABA + ICS in 12 months\*

## Age 6-11 years

**11 Patients** are currently issued  $\leq 2$  SABA + ICS in the previous 12 months\*, compared with **9 at baseline**


The graphs below shows a breakdown of patients with indicators of poor asthma control. To review these patients access **searches 08a to 08d** within the folder named **"03. Issued  $\leq 2$  SABA + ICS"**.



## Age 12+ years

**193 Patients** are currently issued  $\leq 2$  SABA + ICS in the previous 12 months\*, compared with **189 at baseline**

The graphs below shows a breakdown of patients with indicators of poor asthma control. To review these patients access **searches 03a to 03d** within the folder named **"03. Issued  $\leq 2$  SABA + ICS"**.



\* Patients on the Asthma Register excluding those with COPD, on palliative care register or with exercise induced asthma

# Issued 3-5 SABA + ICS in 12 months\*

Patients issued high strength ICS therapy may need referral to severe asthma centres if appropriate for a biologic.

The table below shows a breakdown of patients with indicators of poor asthma control. To review these patients access the **searches 09a-09dii** for those **aged 6-11 years** and **searches 04a-04dii** for those **aged 12+ years** within the folder named **"04. Issued 3-5 SABA + ICS"**.

	Age 6-11 years			Age 12+ years		
	Search Number	Patients Baseline	Patients Re-audit	Search Number	Patients Baseline	Patients Re-audit
<b>Hospital admission or &gt;2 exacerbations</b>	<b>09a.</b>	<b>0</b>	<b>0</b>	<b>04a.</b>	<b>1</b>	<b>0</b>
a. High strength ICS	<b>09ai.</b>	<b>0</b>	<b>0</b>	<b>04ai.</b>	<b>0</b>	<b>0</b>
b. Other ICS	09aii.	0	0	04aii.	1	0
<b>≥2 Systemic OCS</b>	<b>09b.</b>	<b>0</b>	<b>0</b>	<b>04b.</b>	<b>10</b>	<b>6</b>
a. High strength ICS	<b>09bi.</b>	<b>0</b>	<b>0</b>	<b>04bi.</b>	<b>4</b>	<b>1</b>
b. Other ICS	09bii.	0	0	04bii.	6	5
<b>Poor symptom control or ACT &lt;20</b>	<b>09c.</b>	<b>1</b>	<b>2</b>	<b>04c.</b>	<b>10</b>	<b>13</b>
a. High strength ICS	<b>09ci.</b>	<b>0</b>	<b>0</b>	<b>04ci.</b>	<b>2</b>	<b>1</b>
b. Other ICS	09cii.	1	2	04cii.	8	12
<b>Other patients</b>	<b>09d.</b>	<b>14</b>	<b>12</b>	<b>04d.</b>	<b>84</b>	<b>86</b>
a. High strength ICS	<b>09di.</b>	<b>0</b>	<b>0</b>	<b>04di.</b>	<b>12</b>	<b>13</b>
b. Other ICS	09dii.	14	12	04dii.	72	73

\* Patients on the Asthma Register excluding those with COPD, on palliative care register or with exercise induced asthma

# Issued ≥6 SABA + ICS in 12 months\*

Patients issued high strength ICS therapy may need referral to severe asthma centres if appropriate for a biologic.

The table below shows a breakdown of patients with indicators of poor asthma control. To review these patients access the **searches 10a-10dii** for those **aged 6-11 years** and **searches 05a-05dii** for those **aged 12+ years** within the folder named **“05. Issued ≥6 SABA + ICS”**.

	Age 6-11 years			Age 12+ years		
	Search Number	Patients Baseline	Patients Re-audit	Search Number	Patients Baseline	Patients Re-audit
<b>Hospital admission or &gt;2 exacerbations</b>						
a. High strength ICS	10a.	0	0	05a.	6	5
b. Other ICS	10ai.	0	0	05ai.	4	3
	10aii.	0	0	05aia.	2	2
<b>≥2 Systemic OCS</b>	10b.	0	0	05b.	11	13
a. High strength ICS	10bi.	0	0	05bi.	2	4
b. Other ICS	10bii.	0	0	05bii.	9	9
<b>Poor symptom control or ACT &lt;20</b>	10c.	2	1	05c.	22	17
a. High strength ICS	10ci.	0	0	05ci.	5	5
b. Other ICS	10cii.	2	1	05cii.	17	12
<b>Other patients</b>	10d.	0	1	05d.	69	72
a. High strength ICS	10di.	0	0	05di.	11	15
b. Other ICS	10dii.	0	1	05dii.	58	57


\* Patients on the Asthma Register excluding those with COPD, on palliative care register or with exercise induced asthma

# Issued ICS monotherapy (no SABA) in 12 months\*

## Age 6-11 years

**3 Patients** are currently issued **ICS monotherapy (no SABA)** in the previous 12 months\*, compared with **4 at baseline**


The graphs below shows a breakdown of patients with indicators of poor asthma control. To review these patients access **searches 11a to 11d** within the folder named **"06. Issued ICS monotherapy (no SABA)"**.



## Age 12+ years

**195 Patients** are currently issued **ICS monotherapy (no SABA)** in the previous 12 months\*, compared with **191 at baseline**

The graphs below shows a breakdown of patients with indicators of poor asthma control. To review these patients access **searches 06a to 06d** within the folder named **"06. Issued ICS monotherapy (no SABA)"**.



\* Patients on the Asthma Register excluding those with COPD, on palliative care register or with exercise induced asthma

## List of drugs included in High Strength ICS Searches:

Doses (puffs and frequency) of inhalers cannot be identified through clinical system searches. In order to identify ICS devices that deliver high doses, strengths are used in the search criteria.

**Strengths of ICS that can be used to deliver both medium and high doses<sup>8</sup> have been marked with an asterisk (\*).**

### BECLOMETASONE

Beclometasone 200mcg dose inhaler\*

Beclometasone 250mcg dose inhaler

Beclometasone 700mcg breath actuated inhaler CFC free

Clenil Modulite pMDI 250mcg

Kelhale pMDI (extrafine) 100mcg\*

Qvar Autohaler (extrafine) 100mcg\*

Qvar Easi-breathe (extrafine) 700mcg\*

Qvar pMDI (extrafine) 100mcg\*

Soprobec pMDI 250mcg

### BECLOMETASONE/FORMOTEROL

Beclometasone 200mcg / Formoterol 6mcg dry powder inhaler

Beclometasone 200mcg / Formoterol 6mcg inhaler CFC free

Bibecfo 200mcg/dose / 6mcg/dose inhaler

Fostair (NEXThaler) 200/6

Fostair (pMDI) 200/6

Luforbec 200mcg/dose / 6mcg/dose inhaler

Budelin Novolizer 200mcg\*

### BECLOMETASONE/FORMOTEROL/GLYCOPYRRONIUM

Trimbrow pMDI 172mcg/5mcg/9mcg

### BUDESONIDE

Budelin Novolizer 200mcg refill\*

Budesonide 1mg/2ml nebuliser liquid unit dose vials

Budesonide 200mcg dry powder inhalation cartridge

Budesonide 200mcg dry powder inhalation cartridge with refill

Budesonide 400mcg /Formoterol 12mcg dry powder inhaler\*

Budesonide 500mcg/2ml neb liq unit dose vials

Budesonide dry powder inhaler 400mcg

Easyhaler (Budesonide) 400mcg

Pulmicort 1mg Respules

Pulmicort Turbohaler 400mcg\*

### BUDESONIDE/FORMOTEROL

DuoResp Spiromax 320/9\*

Fobumix Easyhaler 320/9\*

Symbicort Turbohaler 400/72\*

WockAIR 320mcg/dose / 9mcg/dose dry powder inhaler\*

## List of drugs included in High Strength ICS Searches:

Doses (puffs and frequency) of inhalers cannot be identified through clinical system searches. In order to identify ICS devices that deliver high doses, strengths are used in the search criteria.

**Strengths of ICS that can be used to deliver both medium and high doses<sup>8</sup> have been marked with an asterisk (\*).**

### CICLESONIDE

Alvesco pMDI 160mcg\*

Ciclesonide 160mcg dose inhaler\*

Ciclesonide cfc-free inhaler 160mcg - 60 doses\*

Ciclesonide cfc-free inhaler 160mcg -120 doses\*

### FLUTICASONE

Flixotide Accuhaler 500mcg

Flixotide Evohaler 250mcg

Fluticasone propionate 500mcg dry powder inhaler

### FLUTICASONE/FORMOTEROL

Asmanex 400mcg/dose Twisthaler

Flutiform MDI 250/70

### FLUTICASONE/SALMETEROL

Aerivio Spiromax 500/50

Airflusal Forspiro 500/50

AirFlusal pMDI 250/25

Aloflute pMDI 250/25

Avenor 25mcg/dose / 250mcg/dose inhaler

Campona Airmaster 50mcg/dose/500mcg/dose dry powder

Combisal pMDI 250/25

Fixkoh Airmaster 50mcg/dose / 500mcg/dose dry powder

Fluticasone 250mcg/ Salmeterol 25mcg inhaler CFC free

Fluticasone 500mcg/ Salmeterol 50mcg inhaler CFC free

Fusacomb Easyhaler 500/50

Sereflo pMDI 250/25

Seretide Accuhaler 500/50

Seretide Evohaler 250/25

Sirdupla pMDI 250/25

Stalpex Orbicel 500/50

### FLUTICASONE/VILANTEROL

Fluticasone furoate 184mcg / Vilanterol 22mcg dry powder inhaler

Relvar Ellipta 184/22

### List of drugs included in Other Strength ICS

This search is created by including patients on all others strengths of inhaled corticosteroids and excluding patients in the high strength ICS group.

### Systemic corticosteroids used in the searches

Drugs in this group include all strengths of tablet, solution, suspension, suppository and injection formulations of Prednisolone.

### Reliever inhalers

Drugs in this group include, all strengths of short-acting beta-2 agonist (SABA):

- Salbutamol
- Terbutaline sulfate



SNOMED Codes that place patients on the QOF Asthma Register<sup>9</sup>

1064811000000100	Moderate acute exacerbation of asthma (disorder)	10742121000119100	Asthma in mother complicating childbirth (disorder)
1064821000000100	Life threatening acute exacerbation of asthma (disorder)	1086701000000100	Life threatening acute exacerbation of allergic asthma (disorder)
10674711000119100	Acute severe exacerbation of asthma co-occurrent with allergic rhinitis (disorder)	1086711000000100	Life threatening acute exacerbation of intrinsic asthma (disorder)
10674791000119100	Acute exacerbation of intermittent allergic asthma	1103911000000103	Severe asthma with fungal sensitisation (disorder)
10674991000119100	Intermittent allergic asthma (disorder)	11641008	Millers' asthma (disorder)
10675391000119100	Severe controlled persistent asthma (disorder)	11944003	Feather-pickers' disease (disorder)
10675431000119100	Severe persistent allergic asthma (disorder)	12428000	Intrinsic asthma without status asthmaticus (disorder)
10675471000119100	Acute severe exacerbation of severe persistent allergic asthma (disorder)	124991000119109	Severe persistent asthma co-occurrent with allergic rhinitis (disorder)
10675551000119100	Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis (disorder)	125001000119103	Moderate persistent asthma co-occurrent with allergic rhinitis (disorder)
10675591000119100	Severe persistent allergic asthma controlled (finding)	125011000119100	Mild persistent asthma co-occurrent with allergic rhinitis (disorder)
10675631000119100	Severe persistent asthma controlled co-occurrent with allergic rhinitis (disorder)	125021000119107	Intermittent asthma co-occurrent with allergic rhinitis (disorder)
10675671000119100	Severe persistent allergic asthma uncontrolled (finding)	13151001	Flax-dressers' disease (disorder)
10675711000119100	Severe persistent asthma uncontrolled co-occurrent with allergic rhinitis (disorder)	135171000119106	Acute exacerbation of moderate persistent asthma
10675751000119100	Severe uncontrolled persistent asthma (disorder)	135181000119109	Acute exacerbation of mild persistent asthma (disorder)
10675871000119100	Mild persistent allergic asthma (disorder)	16584951000119100	Oral steroid-dependent asthma (disorder)
10675911000119100	Acute severe exacerbation of mild persistent allergic asthma (disorder)	1741000119102	Intermittent asthma uncontrolled (disorder)
10675991000119100	Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis (disorder)	1751000119100	Acute exacerbation of chronic obstructive pulmonary disease with asthma (disorder)
10676031000119100	Mild persistent allergic asthma controlled (finding)	18041002	Printers' asthma (disorder)
10676071000119100	Mild persistent asthma controlled (finding)	195949008	Chronic asthmatic bronchitis (d disorder)
10676111000119100	Mild persistent asthma controlled co-occurrent with allergic rhinitis (disorder)	195967001	Asthma (disorder)
10676151000119100	Mild persistent allergic asthma uncontrolled (finding)	195977004	Mixed asthma (disorder)
10676191000119100	Mild persistent asthma uncontrolled (finding)	19849005	Meat-wrappers' asthma (disorder)
10676231000119100	Mild persistent asthma uncontrolled co-occurrent with allergic rhinitis (disorder)	225057002	Brittle asthma (disorder)
10676271000119100	Acute exacerbation of moderate persistent allergic asthma (disorder)	233672007	Byssinosis grade 3 (disorder)
10676351000119100	Moderate persistent asthma controlled (finding)	2733678004	Childhood asthma (disorder)
10676391000119100	Moderate persistent allergic asthma (disorder)	233679003	Late onset asthma (disorder)
10676431000119100	Acute severe exacerbation of moderate persistent allergic asthma (disorder)	233683003	Hay fever with asthma (disorder)
10676511000119100	Acute severe exacerbation of moderate persistent asthma co-occurrent with allergic rhinitis (disorder)	233687002	Colophony asthma (disorder)
10676551000119100	Moderate persistent allergic asthma controlled (finding)	233688007	Sulfite-induced asthma (disorder)
10676591000119100	Moderate persistent controlled asthma co-occurrent with allergic rhinitis (disorder)	233691007	Asthmatic pulmonary eosinophilia (disorder)
10676631000119100	Moderate persistent allergic asthma uncontrolled (finding)	2360001000004100	Steroid dependent asthma (disorder)
10676671000119100	Moderate persistent asthma uncontrolled co-occurrent with allergic rhinitis (disorder)	266361008	Non-allergic asthma (disorder)
10676711000119103	Moderate persistent asthma uncontrolled (finding)	281239006	Exacerbation of asthma (disorder)
10692721000119100	Chronic obstructive asthma co-occurrent with acute exacerbation of asthma (disorder)	30352005	Allergic-infective asthma (disorder)
10692761000119100	Asthma-chronic obstructive pulmonary disease overlap syndrome (disorder)	304527002	Acute asthma (disorder)

SNOMED Codes that place patients on the QOF Asthma Register<sup>9</sup>

312453004	Asthma - currently active (finding)	703953004	Allergic asthma caused by Dermatophagoides pteronyssinus (disorder)
31387002	Exercise-induced asthma (disorder)	703954005	Allergic asthma caused by Dermatophagoides farinae (disorder)
34015007	Bakers' asthma (disorder)	707444001	Uncomplicated asthma (disorder)
370218001	Mild asthma (disorder)	707445000	Exacerbation of mild persistent asthma (disorder)
370219009	Moderate asthma (disorder)	707446004	Exacerbation of moderate persistent asthma (disorder)
370220003	Occasional asthma (disorder)	707447008	Exacerbation of severe persistent asthma (disorder)
370221004	Severe asthma (disorder)	707511009	Uncomplicated mild persistent asthma (disorder)
389145006	Allergic asthma (disorder)	707512002	Uncomplicated moderate persistent asthma (disorder)
401000119107	Asthma with irreversible airway obstruction (disorder)	707513007	Uncomplicated severe persistent asthma (disorder)
401193004	Asthma confirmed (situation)	707979007	Acute severe exacerbation of severe persistent asthma (disorder)
404804003	Platinum asthma (disorder)	707980005	Acute severe exacerbation of moderate persistent asthma (disorder)
404806001	Cheese-makers' asthma (disorder)	707981009	Acute severe exacerbation of mild persistent asthma (disorder)
404808000	Isocyanate induced asthma (disorder)	708038006	Acute exacerbation of asthma (disorder)
405944004	Asthmatic bronchitis (disorder)	708090002	Acute severe exacerbation of asthma (disorder)
407674008	Aspirin-induced asthma (disorder)	708093000	Acute exacerbation of immunoglobulin E-mediated allergic asthma (disorder)
409663006	Cough variant asthma (disorder)	708094006	Acute exacerbation of intrinsic asthma (disorder)
41553006	Detergent asthma (disorder)	708095007	Acute severe exacerbation of immunoglobulin E-mediated allergic asthma (disorder)
418395004	Tea-makers' asthma (disorder)	708096008	Acute severe exacerbation of intrinsic asthma (disorder)
423889005	Non-immunoglobulin E mediated allergic asthma	72301000119103	Asthma in pregnancy (disorder)
424199006	Substance induced asthma (disorder)	733858005	Acute severe refractory exacerbation of asthma (disorder)
424643009	Immunoglobulin E-mediated allergic asthma (disorder)	734904007	Life threatening acute exacerbation of asthma (disorder)
425969006	Exacerbation of intermittent asthma (disorder)	734905008	Moderate acute exacerbation of asthma (disorder)
426656000	Severe persistent asthma (disorder)	735587000	Acute severe exacerbation of asthma co-occurrent and due to allergic asthma (disorder)
426979002	Mild persistent asthma (disorder)	735588005	Uncomplicated allergic asthma (disorder)
427295004	Moderate persistent asthma (disorder)	735589002	Uncomplicated non-allergic asthma (disorder)
427603009	Intermittent asthma (disorder)	762521001	Exacerbation of allergic asthma (disorder)
427679007	Mild intermittent asthma (disorder)	782520007	Exacerbation of allergic asthma due to infection (disorder)
442025000	Acute exacerbation of chronic asthmatic bronchitis	786836003	Near fatal asthma (disorder)
445427006	Seasonal asthma (disorder)	829976001	Thunderstorm asthma (disorder)
55570000	Asthma without status asthmaticus (disorder)	85761009	Byssinosis (disorder)
56968009	Asthma caused by wood dust (disorder)	866881000000101	Chronic asthma with fixed airflow obstruction (disorder)
57607007	Occupational asthma (disorder)	89099002	Chronic allergic bronchitis (disorder)
59786004	Weavers' cough (disorder)	92807009	Chemical-induced asthma (disorder)
63088003	Allergic asthma without status asthmaticus (disorder)	93432008	Drug-induced asthma (disorder)
641000119106	Intermittent asthma well controlled (finding)	99031000119107	Acute exacerbation of asthma co-occurrent with allergic rhinitis (disorder)

# References

1. Journal of Allergy and Clinical Immunology (Volume 153, Issue 5, May 2024, Pages 1181-1193) - Airway hyperresponsiveness in asthma: The role of the epithelium:  
Available from: <https://www.sciencedirect.com/science/article/pii/S009167492400191X>  
[Last Accessed: December 2024]
2. NICE CKS - What is the prevalence of asthma?  
Eur Respir J. 2019;53:1802130.  
Available from: <https://cks.nice.org.uk/topics/asthma/background-information/prevalence/>  
[Last Accessed: December 2024]
3. Bloom, C.I., Cabrera, C., Arnetorp, S. et al. Asthma-Related Health Outcomes Associated with Short-Acting Beta-2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program. Adv Ther 37, 4190–4208 (2020).  
Available from: <https://doi.org/10.1007/s12325-020-01444-5>  
[Last Accessed: December 2024]
4. Asthma: effect of excess short-acting beta-2-agonist (SABA) inhaler prescriptions on healthcare resource utilisation; British Journal of General Practice 2024; 74 (745): 374-376.  
Available from: <https://bjgp.org/content/74/745/374.short>  
[Last Accessed: December 2024]
5. What is severe asthma? Severe asthma - the most serious type of asthma.  
Available from: <https://www.asthmaandlung.org.uk/conditions/severe-asthma/what-severe-asthma>  
[Last Accessed: December 2024]
6. QOF data 2023/24  
Available from: <https://digital.nhs.uk/data-and-information/publications/statistical/quality-and-outcomes-framework-achievement-prevalence-and-exceptions-data/2023-24#resources>  
[Last Accessed: December 2024]
7. GMS SFE 2024-2025.  
Available from: <https://assets.publishing.service.gov.uk/media/66f6bde1e84ae1fd8592eabd/general-medical-services-statement-of-financial-entitlements-directions-2024.pdf>  
[Last Accessed: December 2024]
8. BTS and SIGN (2019) British guideline on the management of asthma (SIGN 158). British Thoracic Society and Scottish Intercollegiate Guidelines Network.  
Available from: <https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma>  
[Last Accessed: December 2024]
9. SNOMED Codes  
Available from: <https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/quality-and-outcomes-framework-qof/quality-and-outcome-framework-qof-business-rules/primary-care-domain-reference-set-portal>  
[Last Accessed: December 2024]